Stressgen announces changes to its Board of Directors

SAN DIEGO, CA, April 6 /CNW/ - Stressgen Biotechnologies Corporation
(TSX:SSB) ("Stressgen") announced that effective today, Robert Rieder, Vice
Chairman and Chief Executive Officer of Cardiome Pharma Corp., has joined the
Board of Directors. In addition, Jay M. Short, Ph.D. has been appointed
Chairman of the Board replacing R. Ian Lennox who announced his resignation
from the Board.
"We are extremely pleased with Bob Rieder's appointment to our Board of
Directors," commented Gregory M. McKee, President and Chief Executive Officer.
"We believe his extensive experience in the healthcare industry and exemplary
track record building Cardiome Pharma make him an ideal addition to our Board.
We are also pleased that Jay Short has agreed to serve as Chairman, providing
continued scientific and business leadership. We would like to take this
opportunity to sincerely thank Ian Lennox for his dedicated service and
significant contribution to the Company."
Mr. Rieder joined Cardiome in April of 1988 as President and Chief
Executive Officer, and was recently appointed as the Company's Vice Chairman
of the Board. Mr. Rieder has extensive experience in venture capital and in
operational management. Prior to joining Cardiome, he was Vice President at
MDS Ventures Pacific Inc., the Vancouver-based affiliate of MDS Capital Corp.,
and has served as a director for nine public and private technology companies.
In his venture capital career, Mr. Rieder led several rounds of financing for
Stressgen and was a director of the Company from 1992 until 2000. Prior to
joining MDS, Mr. Rieder was President and Chief Executive Officer of Synapse
Technologies and Chief Operating Officer of DBA Telecom Inc. Mr. Rieder
received his BASc (Chem. Eng.) from the University of British Columbia and his
MBA from the University of Western Ontario.
Dr. Short has served on the Stressgen Board of Directors for twelve
years. In 2005, Dr. Short became Chairman, President and Founder of the E. O.
Wilson Biodiversity Foundation in San Diego, California. Dr. Short served as
President, Chief Executive Officer, Chief Technology Officer, Director and
Founder of Diversa Corporation from September 1994 to October 2005.

About Stressgen Biotechnologies Corporation:

Stressgen is developing innovative therapeutics for the treatment of
viral infections, with a focus on diseases caused by the human papillomavirus
(HPV). The corporation is publicly traded on the Toronto Stock Exchange under
the symbol SSB. For more information about Stressgen, please visit the website
located at www.stressgen.com.


%SEDAR: 00002379E